All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. - Wikidata - wikimedia - TriplyDB

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.

http://www.wikidata.org/entity/Q35954490

about

Immunotoxicity of monoclonal antibodies Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritis Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study.Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database.Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis.The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.Biologics and heart failure in rheumatoid arthritis: are we any wiser?Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis.The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.Treating rheumatic patients with a malignancy.Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review.Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs Association between anti-TNF-α therapy and all-cause mortality Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.Tumor necrosis factor inhibitors and infection complications.Cardiovascular co-morbidity in rheumatic diseases.Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.Update on the use of etanercept across a spectrum of rheumatoid disorders.Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases How safe are the biologicals in treating asthma and rhinitis?Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review.Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis.Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review.Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence.

P2860

Q24653374-9AACE3BA-5AA6-48B8-A093-6B2D25338E9A Q26822912-8D95A1BA-A820-48D8-82C7-C5B01F58AAC3 Q26852081-910708ED-19CF-49E0-B6E1-C6AD0DBDFE65 Q28709376-37B6A912-DCE9-483C-BB94-E2F7620FCB60 Q30240180-9E3E6373-B18B-46CE-9732-6480262EBC1F Q30240183-3601C478-FB00-4627-973D-920D8D01E4F6 Q30494937-821D6215-7585-49BE-9F5F-B8E27E7D3F13 Q30680371-17DE9D33-7C1C-4940-95A5-E10DEB12C73F Q30731527-E55CE24F-747F-4482-961D-609E91A25F79 Q33346685-30F3333C-2DD9-4DB1-B3C7-EB8BF9F4AEBF Q33478325-50B86BE3-B139-48E9-9F1E-A99C62192035 Q33529391-60E2AD29-889F-42C6-A1C8-858DAE2AE6AB Q33602465-DE229AD7-0096-43C7-BD81-D3914AC96450 Q33687843-8FDE87D6-13E8-493F-9641-2E884A51A095 Q33892790-336C865B-19EA-44E1-8A70-041175FB447A Q33898103-F4563DD5-5DC3-4582-AD51-6A6E2D4D9820 Q34658023-2BA2E40A-790C-4F47-85D3-26E9A006419A Q34699641-B4E16345-4D87-45FF-A36D-4BEB24F7E6EC Q34818636-CC519BCF-56E7-41FC-B8F9-DB26CA9E6924 Q35092457-D490729B-AA49-4BC5-953E-0AD22CF24F1D Q35135831-8C672FEB-3C39-49F3-A6A3-6FA64FF8A0F2 Q35557863-8E9B4F44-794F-4B33-BD3B-3CB73327170D Q35617617-195BD8F7-3FB2-4116-8418-F34C3B98B678 Q35705082-DD69B738-C1D7-44BC-8BE6-954339BD01C6 Q36182351-7FE1A6D0-84E2-43D4-ABF7-D886B824E02E Q36361147-9C01A747-CB3A-414A-8F92-60C3525FA0B6 Q36590690-3E6A287B-E18A-4C0E-9204-C8108A961005 Q36677345-2DCF1702-59F4-4FE9-970E-2C2B0066C31F Q36757060-F283B492-20DF-4B93-B81F-B43153FDCADD Q36806922-26B78096-07DA-401F-94FF-3BC8F3490F6C Q36835851-CFA4CF98-9F32-45A2-BA08-2F270BBB81E9 Q36901936-20449034-9021-4006-AD53-DEF743154351 Q37290628-7D40DC92-BC55-4C72-AFFE-C3615FB0CF0D Q37404893-DB901462-CF1D-4FC5-96B6-9BEA5303FAC1 Q37479670-B74830E7-58F8-4D9A-976B-8147FF704596 Q37632485-B11AE305-5EEC-400B-866D-600ED38D17A1 Q37801353-3669C214-A236-45E5-BF20-E0457514CD4B Q37808889-ED619BE4-4D0A-4827-B5D1-F53DC6523C04 Q37838346-2074183B-E402-425F-BF09-C488679863B2 Q37907921-E89D11E7-231A-4CA5-A61D-C95DAB0DA313

P2860

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.

http://www.wikidata.org/entity/Q35954490

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

All-cause and cause-specific m ...... r necrosis factor antagonists.

@ast

All-cause and cause-specific m ...... r necrosis factor antagonists.

@en

type

label

All-cause and cause-specific m ...... r necrosis factor antagonists.

@ast

All-cause and cause-specific m ...... r necrosis factor antagonists.

@en

prefLabel

All-cause and cause-specific m ...... r necrosis factor antagonists.

@ast

All-cause and cause-specific m ...... r necrosis factor antagonists.

@en

P1433

Q35954490-D463B0B4-4976-4ED3-97AF-F5069026E7DE

P1476

Q35954490-5C10ECFB-C62B-40B0-9E3D-1E9BDE2CA745

P2093

Q35954490-1EE2F964-C8AC-46B2-BB22-E8738DB63AD2

Q35954490-29217826-A0DA-4949-98AF-1F15784AF4A5

Q35954490-36B2FB26-0BE4-4D43-BBA7-ECBB8BB47B6A

Q35954490-AD75DEAC-B35C-4C64-BA6C-5FA9354758F7

Q35954490-DEE3BF50-7E6C-4101-A73D-E529018F52A9

Q35954490-F7219D0B-041B-4F38-AFB7-C5C0553AE132

Q35954490-F9255EFA-6A7C-46A5-893C-F6EB13B4D232

P2860

Q35954490-04FD4118-487C-49D7-8444-A6E5667F55B8

Q35954490-06D24B74-3B82-464D-AE16-95F847F22536

Q35954490-0CF65D4C-DAC0-454B-AC6E-36A9209F00BE

Q35954490-0DF44A5A-0A6D-42BA-AAB2-8DAB315237EC

Q35954490-188534B4-BF40-4DDB-90D2-D6E93CEAF509

Q35954490-1A380453-7EAE-4404-92D2-F3A1E6F909C9

Q35954490-1F9EC035-2F5E-4B0A-BFE3-9F0607E74D8E

Q35954490-26998CF2-6BD8-4F66-A290-A082346AE169

Q35954490-2C85C188-9A4E-4250-838E-16773F9BD45F

Q35954490-400A6C43-C1C7-4D09-96E0-25D1B3D3C271

P304

Q35954490-1D44FFD9-F021-49A4-9BDC-7CC3B7344E73

P31

Q35954490-0D6EEE21-95FE-4234-9A68-1AA0B7FB1003

P356

Q35954490-68D6F306-2E54-46DF-9980-91E56E732E33

P407

Q35954490-52EE6E5B-37FE-4684-9115-D0AC0F06EFFA

P433

Q35954490-4B2DA394-ADFA-4E9D-95F1-74024CFAFC21

P478

Q35954490-A64603B4-B366-494B-B5D4-4B85003C6A11

P50

Q35954490-7822C8DE-A016-44B8-A7FE-EA2A2922E63D

P577

Q35954490-81DA9758-0185-48E6-8CB1-D554B6FE49CF

P5875

Q35954490-47405215-73A1-4B04-8B29-FD1761A5BE94

P698

Q35954490-8C607592-E19B-4570-BFE9-2FC1408E389B

P921

Q35954490-b13e6902-d814-4dfc-95e2-c688ea2c3d91

P932

Q35954490-40EF3C92-8770-4D4C-A281-6243B7B3CDE8

P356

ARD.2006.067660

P1433

Annals of the Rheumatic Diseases

P1476

All-cause and cause-specific m ...... r necrosis factor antagonists.

@en

P2093

Alba Erra

http://www.w3.org/2001/XMLSchema#string

BIOBADASER and EMECAR Groups

http://www.w3.org/2001/XMLSchema#string

Dolores Ruiz-Montesinos

http://www.w3.org/2001/XMLSchema#string

Eva Perez-Pampin

http://www.w3.org/2001/XMLSchema#string

Juan J Gómez-Reino

http://www.w3.org/2001/XMLSchema#string

Miguel Angel Descalzo

http://www.w3.org/2001/XMLSchema#string

Tatiana Cobo

http://www.w3.org/2001/XMLSchema#string

P2860

Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity

Atherosclerosis — An Inflammatory Disease

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients.

Invited commentary: propensity scores.

The mortality of rheumatoid arthritis.

Coronary artery disease and rheumatoid arthritis.

Side effects of anti-TNF therapy: current knowledge.

Infections and biological therapy in rheumatoid arthritis.

Mortality in rheumatoid arthritis patients with disease onset in the 1980s.

P304

880-885

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2006.067660

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6481377

http://www.w3.org/2001/XMLSchema#string

P698

17324968

http://www.w3.org/2001/XMLSchema#string

P921

P932

1955107

http://www.w3.org/2001/XMLSchema#string